Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457729 | 1.00 | TSHR (0.51) | TSHRPKMLMNAALDH1A1L3MBTL1 | |
| SCHEMBL21600709 | 0.84 | PSIP1 (0.36) | PKMLMNAALDH1A1GAA | |
| SCHEMBL24246845 | 0.82 | PTGS2 (0.36) | TSHRLMNAALDH1A1POLBGAA | |
| SCHEMBL21600738 | 0.81 | ALDH1A1 (0.39) | PKMALDH1A1L3MBTL1POLB | |
| SCHEMBL21600743 | 0.81 | CYP3A4 (0.37) | TSHRLMNAALDH1A1GAA | |
| SCHEMBL21600740 | 0.81 | MMP2 (0.37) | ALDH1A1 | |
| SCHEMBL23142584 | 0.80 | MCOLN3 (0.35) | LMNAALDH1A1POLBKCNH2KDM4E | |
| SCHEMBL21600730 | 0.80 | MMP13 (0.42) | PKMLMNAALDH1A1 | |
| SCHEMBL24246859 | 0.80 | GAA (0.38) | TSHRLMNAALDH1A1L3MBTL1GAA | |
| SCHEMBL21600725 | 0.80 | DDB1 (0.41) | ALDH1A1L3MBTL1SLC6A2SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| WO-2019242692-A1 | COMPOUND AND USE THEREOF IN SYNTHESIS OF BRIVARACETAM INTERMEDIATE AND CRUDE DRUG | 福建海西新药创制有限公司 | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | CYP3A43, POR, CYP2C19 | TSHR 1675/4885PKM 32/4885LMNA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.